Improving treatment for glioblastoma with MDM2 inhibitors
Maximizing the efficacy of MDM2 inhibitor therapy for MDM2-amplified glioblastoma
['FUNDING_R01'] · MAYO CLINIC ROCHESTER · NIH-10984798
This study is looking at how a new treatment called brigimadlin can help patients with a specific type of aggressive brain tumor by making the cancer cells die, and it aims to see if this can lead to better results for those with MDM2-amplified glioblastoma.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-10984798 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness of MDM2 inhibitor therapy specifically for patients with MDM2-amplified glioblastoma, a type of aggressive brain tumor. The study investigates how these inhibitors can trigger cancer cell death by disrupting the MDM2/p53 pathway, which is crucial for tumor growth. Researchers will explore the mechanisms behind the sensitivity of these tumors to the MDM2 inhibitor brigimadlin, assessing its impact on apoptosis and DNA repair processes. Patients may be treated with this drug to see if it can improve outcomes for those with this specific genetic alteration.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with MDM2-amplified glioblastoma.
Not a fit: Patients without MDM2 amplification or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with MDM2-amplified glioblastoma, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with MDM2 inhibitors in similar contexts, indicating potential for success in this approach.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SARKARIA, JANN N. — MAYO CLINIC ROCHESTER
- Study coordinator: SARKARIA, JANN N.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.